ARTRYA

Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT MARKET RELEASE

28 November 2024

RESULTS OF ANNUAL GENERAL MEETING

Artrya Limited (ASX:AYA), ('Artrya' or the 'Company'), a medical technology company focused on commercialising its patented artificial intelligence platform that detects key coronary artery disease imaging markers, advises that the resolutions considered at today's Annual General Meeting of Shareholders were all passed on a poll.

The Company advises that Resolution 5 being a special resolution was passed by a sufficient majority.

In accordance with listing rule 3.13.2 and section 251AA of the Corporations Act the details of the votes cast on each of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

This announcement was approved by the Artrya Board.

For further information please contact:

Investor Enquiries:

Danny Younis +61 420 293 042

danny.younis@automicgroup.com.au

Media Relations:

Tristan Everett +61 403 789 096

tristan.everett@automicgroup.com.au

About Artrya

Based in Perth, Australia, Artrya was founded in 2018 with operations starting in early 2019. The Company was listed on the Australian Securities Exchange (ASX: AYA) in 2021.

Artrya is an applied artificial intelligence healthcare company that works alongside clinicians to improve the diagnosis of coronary heart disease and develop a holistic overview of at-risk patients. The company has developed deep-learning algorithms pending regulatory submission for clearance and approval in the US that will serve to predict and prevent acute coronary events.

For more information, see www.artrya.com

Artrya Limited ACN 624 005 741 1257 Hay Street West Perth WA 6005 PO Box 567 West Perth WA 6872 www.artrya.com

T: +61 8 6478 7816

Disclosure of Proxy Votes

Artrya Limited

Annual General Meeting Thursday, 28 November 2024



GPO Box 5193, Sydney, NSW 2001 P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world) F +61 (0)2 8583 3040 E hello@automic.com.au ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	ОИТСОМЕ
1 ADOPTION OF REMUNERATION REPORT	Р	31,349,356	28,926,807 92.27%	25,000 0.08%	2,045,218	2,397,549 7.65%	36,765,276 99.93%	25,000 0.07%	2,045,218	-
2 RE-ELECTION OF DR JACQUE SOKOLOV AS A DIRECTOR	Р	36,090,340	33,676,791 93.31%	16,000 0.04%	2,341,818	2,397,549 6.64%	41,515,260 99.96%	16,000 0.04%	2,341,818	Carried
3 RATIFICATION OF PRIOR ISSUE OF PERFORMANCE OPTIONS TO CONE HEALTH	Р	36,416,940	33,987,391 93.33%	32,000 0.09%	2,015,218	2,397,549 6.58%	41,825,860 99.92%	32,000 0.08%	2,015,218	Carried
4 RATIFICATION OF PRIOR ISSUE OF PERFORMANCE OPTIONS TO TANNER HEALTH	Р	36,416,940	33,987,391 93.33%	32,000 0.09%	2,015,218	2,397,549 6.58%	41,825,860 99.92%	32,000 0.08%	2,015,218	Carried
5 APPROVAL OF 7.1A MANDATE	Р	36,336,940	33,864,727 93.20%	74,664 0.21%	2,095,218	2,397,549 6.60%	41,753,196 99.82%	74,664 0.18%	2,045,218	Carried
6 APPROVAL TO ISSUE OPTIONS IN CONSIDERATION FOR SERVICES RENDERED - BEITH CAPITAL ADVISORY LLC	Р	36,416,940	33,987,391 93.33%	32,000 0.09%	2,015,218	2,397,549 6.58%	41,825,860 99.92%	32,000 0.08%	2,015,218	Carried
7 APPROVAL TO ISSUE OPTIONS IN CONSIDERATION FOR SERVICES RENDERED - L DAVINCI LLC	Р	36,336,940	33,907,391 93.31%	32,000 0.09%	2,095,218	2,397,549 6.60%	41,795,860 99.92%	32,000 0.08%	2,045,218	Carried
8 APPROVAL TO INCREASE MAXIMUM SECURITIES UNDER THE COMPANY'S EMPLOYEE INCENTIVE PLAN	Р	24,206,412	21,817,633 90.13%	79,174 0.33%	2,188,162	2,309,605 9.54%	29,618,158 99.73%	79,174 0.27%	2,138,162	Carried